12 Result(s)

Article

Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials

We sought to identify patient subgroups with distinct postprogression overall survival (ppOS) outcomes and investigate the impact of original treatment assignment and initial postprogression treatment (ppRx) o...

Paolo A. Ascierto, Antoni Ribas, James Larkin… in Journal of Translational Medicine (2020)

Article

FASCE, the benefit of spironolactone for treating acne in women: study protocol for a randomized double-blind trial

Acne vulgaris has increased in women over the past 10 years; it currently affects 20–30% of women. The physiopathology of adult female acne is distinguished from that of teenagers essentially by two factors: h...

Alexandra Poinas, Marie Lemoigne, Sarah Le Naour, Jean-Michel Nguyen… in Trials (2020)

Article

CICAFAST: comparison of a biological dressing composed of fetal fibroblasts and keratinocytes on a split-thickness skin graft donor site versus a traditional dressing: a randomized controlled trial

Wound repair is one of the most complex biological processes of human life. Allogeneic cell-based engineered skin substitutes provide off-the-shelf temporary wound coverage and act as biologically active dress...

Alexandra Poinas, Pierre Perrot, Judith Lorant, Olivier Nerrière… in Trials (2019)

Article

Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM

This pooled analysis investigated the prognostic value of depth of response in two cohorts of patients with BRAF^V600-mutated metastatic melanoma treated with vemurafenib or cobimetinib plus vemurafenib.

Karl D. Lewis, James Larkin, Antoni Ribas, Keith T. Flaherty… in British Journal of Cancer (2019)

Article

Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAF^V600 mutation–positive melanoma

In the coBRIM study, cobimetinib plus vemurafenib (C+V) significantly improved survival outcomes vs placebo and vemurafenib (P+V) in patients with advanced/metastatic BRAF^V600-mutated melanoma. An analysis of hea...

Brigitte Dréno, Paolo A Ascierto, Victoria Atkinson… in British Journal of Cancer (2018)

Article

Efficient treatment of a metastatic melanoma patient with a combination of BRAF and MEK inhibitors based on circulating tumor DNA analysis: a case report

Fixed tissues are the standard samples used in routine practice for molecular testing. But sometimes tissues are lacking or difficult to obtain. In these cases, circulating tumor DNA released from tumor cells ...

Gaelle Quéreux, Guillaume Herbreteau, Anne-Chantal Knol… in BMC Research Notes (2017)

Article

Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study

Serous chorioretinopathy has been associated with MEK inhibitors, including cobimetinib. We describe the clinical features of serous retinopathy observed with cobimetinib in patients with BRAF ...

Luis de la Cruz-Merino, Lorenza Di Guardo… in Journal of Translational Medicine (2017)

Article

Melanoma and immunotherapy bridge 2015

MELANOMA BRIDGE 2015

Vashisht G. Y. Nanda, Weiyi Peng, Patrick Hwu… in Journal of Translational Medicine (2016)

Article

coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAF^V600 mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519)

Paolo A Ascierto, Grant A. McArthur, Brigitte Dréno… in Journal of Translational Medicine (2015)

Article

A subset of dendritic cells as a major and constitutive source of IL-22BP

Jérôme Martin, Gaelle Bériou, Michèle Heslan… in Journal of Translational Medicine (2011)

Article

Value of large scale expansion of tumor infiltrating lymphocytes in a compartmentalised gas-permeable bag: interests for adoptive immunotherapy

Adoptive cell therapy (ACT) has emerged as an effective treatment for patients with metastatic melanoma. However, there are several logistical and safety concerns associated with large-scale ex vivo expansion of ...

Thomas Zuliani, Julien David, Sylvain Bercegeay… in Journal of Translational Medicine (2011)